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A B S T R A C T
Background: Anxious depression is an important subtype of Major Depressive Disorder (MDD) defined by both
syndromal (anxiety disorders) and dimensional (anxiety symptoms) criteria. A debated question is how anxiety
affects MDD treatment. This study examined the impact of comorbid anxiety disorders and symptoms on the
effectiveness of and dropout during Cognitive Therapy (CT) and Interpersonal Psychotherapy (IPT) for MDD.
Methods: Depressed individuals were randomized to CT (n=76) or IPT (n=75). Outcome was depression
severity measured with the Beck Depression Inventory-II (BDI-II) at the start of each therapy session, post
treatment, and monthly up to five months follow-up. Anxiety disorders were assessed with the Structured
Clinical Interview for DSM-IV Axis I disorders, (phobic) anxiety symptoms were assessed with Brief Symptom
Inventory subscales.
Results: Approximately one third of participants had a comorbid anxiety disorder. Comorbid anxiety disorders
and anxiety symptoms were associated with less favorable depression change during IPT as compared to CT in
the treatment phase, but not in the trial follow-up phase. Individuals with a comorbid anxiety disorder had
significantly higher treatment dropout during both treatments.
Limitations: Not all therapists and participants were blind to the assessment of comorbid anxiety disorders and
the assessments were performed by one rater.
Conclusions: A preference for CT over IPT for MDD is justifiable when comorbid anxiety is present, although
long-term differences are not established and replication of this finding is needed. Clinicians should be aware of
the risk of dropout for depressed individuals with an anxiety disorder.
1. Introduction
Given high comorbid anxiety in Major Depressive Disorder (MDD),
anxious depression is considered to be an important subtype (American
Psychiatric Association, 2013; Rao and Zisook, 2009; Ten Have et al.,
2016). This subtype can be defined as MDD with a comorbid anxiety
disorder (syndromal definition) or subthreshold comorbid anxiety
symptoms (dimensional definition) (Ionescu et al., 2013; Rao and
Zisook, 2009). For both definitions, anxious depression has been asso-
ciated with a severe clinical picture including more severe depressive
symptoms (Brown et al., 1996; Fava et al., 2004; Penninx et al., 2011;
Smits et al., 2009), more functional impairment (Fava et al., 2004;
Smits et al., 2009) and intensified suicidal thoughts and behavior
(Brown et al., 1996; Fava et al., 2004; Fawcett et al., 1990; Pfeiffer
et al., 2009). With these profound clinical disadvantages, one could
expect an adverse effect of comorbid anxiety on MDD treatment out-
come and treatment continuation. However, findings regarding the
impact of comorbid anxiety on MDD treatment outcome and dropout
are inconsistent for both pharmacotherapy and psychotherapy, and
there has been little agreement on tailored treatment recommendations.
Studies examining the effects of antidepressants found that in-
dividuals with comorbid anxiety disorders had less favorable outcomes
(Howland et al., 2009; Lee et al., 2012) and higher dropout rates
(Arnow et al., 2007; Howland et al., 2009). In contrast to anxiety
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disorders, the impact of comorbid anxiety symptoms on MDD outcome
varied from lower response and remission rates (Davidson et al., 2002;
Fava et al., 2008; Flint and Rifat, 1997; Frank et al., 2011; Papakostas
et al., 2008; Wiethoff et al., 2010) to no adverse effects (Forand and
Derubeis, 2013; Fournier et al., 2009; Joffe et al., 1993; Nelson, 2010;
Russell et al., 2001; Tollefson et al., 1994). In addition, anxiety symp-
toms were not associated with dropout in other antidepressant trials
(Flint and Rifat, 1997; Fournier et al., 2009; Russell et al., 2001;
Tollefson et al., 1994; Wiethoff et al., 2010).
In psychotherapy research, findings on the influence of comorbid
anxiety on treatment outcome and continuation are even more incon-
clusive. Two effective and frequently applied psychotherapies for MDD
are Cognitive Therapy (CT) and Interpersonal Psychotherapy (IPT).
Most of the psychotherapy studies that examined the impact of co-
morbid anxiety on MDD outcome focused on CT. Overall, CT studies did
not show an adverse effect of anxiety on MDD outcome. Several studies
showed similar treatment outcomes for individuals with and without
anxiety disorders or with and without anxiety symptoms (Brent et al.,
1998; Forand and Derubeis, 2013; Fournier et al., 2009; McEvoy and
Nathan, 2007; Persons et al., 2006; Smits et al., 2009). Surprisingly,
other CT studies reported a more accelerated depressive symptom im-
provement when comorbid anxiety disorders or symptoms were present
(de Azevedo Cardoso et al., 2014; Forand et al., 2011; Kashdan and
Roberts, 2011; Rohde et al., 2001; Smits et al., 2012). With regard to
treatment continuation, in the majority of CT studies, anxiety disorders
(Forand et al., 2011; Kashdan and Roberts, 2011; Rohde et al., 2001;
Schindler et al., 2013; Smits et al., 2009) and anxiety symptoms
(Forand et al., 2011; Fournier et al., 2009; McEvoy and Nathan, 2007;
Smits et al., 2012) did not affect treatment dropout, although one study
reported higher dropout rates for individuals with a comorbid anxiety
disorder (Arnow et al., 2007). For IPT, fewer findings on the impact of
comorbid anxiety on MDD treatment outcome and completion are
available. In contrast to CT, findings of these studies suggest an adverse
effect of (lifetime) anxiety disorders and anxiety symptoms on MDD
outcome (Brown et al., 1996; Frank et al., 2011, 2000; Young et al.,
2006). In addition, one study reported higher dropout rates for in-
dividuals with lifetime anxiety disorders as compared to individuals
without lifetime anxiety disorders (Brown et al., 1996). To date, there
are no head-to-head comparisons of CT and IPT focusing on anxious
depression, although one study showed that axis I disorders in general
did not predict (differential) MDD treatment outcomes for CT and IPT
(Carter et al., 2011).
A possible explanation for these mixed results is the use of different
definitions to classify anxious depression (Ionescu et al., 2013). This
concern is illustrated by a recent study that showed that the syndromal
and dimensional definitions of anxious depression classify two different
groups of individuals under the same “anxious depression” label (van
der Veen et al., 2014). This lack of overlap is not surprising; the syn-
dromal definition refers to two distinct disorders, while the dimensional
criteria define a certain subtype of depression. These different con-
ceptualizations of anxious depression are however a major concern for
integrating the outcomes of previous studies into broader knowledge
and translating findings to clinical practice. In addition, mixed results
could be explained by small study samples and the different measures of
anxiety disorders and anxiety symptoms. Anxiety disorders diagnoses
are measured both lifetime and current, with different types of instru-
ments. Furthermore, diagnosing a distinct anxiety disorder from an
acute phase depression can be challenging. For anxiety symptoms, some
studies used specific anxiety oriented instruments while others used the
Anxiety/ Somatization Factor of the Hamilton Rating Scale for De-
pression ( Fava et al., 2000).
The aim of this study was to examine the (differential) effect of
comorbid anxiety on the effectiveness and treatment continuation of CT
and IPT for MDD in a head-to-head comparison. In order to confirm the
assumption that the syndromal definition of anxious depression is dif-
ferent from the dimensional one, the impact of anxiety disorders,
anxiety symptoms (i.e. generalized anxiety symptoms), and phobic
anxiety symptoms (i.e. agoraphobic symptoms) was examined sepa-
rately. Based on previous studies, we expected no adverse effect of
comorbid anxiety on MDD treatment outcomes and completion for CT.
Based on the limited research available for IPT, one could expect less
favorable outcomes and higher dropout rates for individuals with co-
morbid anxiety disorders or symptoms treated with IPT.
2. Method
2.1. Study design
Data were collected in the context of a randomized controlled trial
examining the effectiveness of CT and IPT for MDD. Individuals with a
primary MDD diagnosis as confirmed with the Structured Clinical
Interview for DSM-IV Axis I disorders (SCID-I, First et al., 1995) by
trained clinicians were recruited from the mood disorders unit of the
Maastricht Outpatient Mental Health Center (RIAGG Maastricht). Ad-
ditional inclusion criteria were: internet access, an email address, and
sufficient knowledge of the Dutch language. Exclusion criteria were a
bipolar or chronic depression (current episode> 5 years), elevated
acute suicide risk, concomitant pharmacological or psychological
treatment, drugs and alcohol abuse/dependence, and mental retarda-
tion (IQ< 80). A total of 1562 individuals were screened for eligibility.
Of these 1562 individuals, 1191 did not meet the inclusion criteria
(main reasons were the use of antidepressant medication (n= 362) or
MDD not being the primary diagnosis (n= 434), 78 patients met in-
clusion criteria but refused to participate, and 111 were excluded for
other reasons. A total of 182 depressed outpatients were randomly al-
located to CT (n=76), IPT (n=75), or a 2-month waiting-list control
condition followed by treatment of choice (n=31). For the current
analyses, we limited the sample to data of individuals randomized to
the active conditions CT and IPT (n=151) in the acute phase of
therapy (month 0 – 7) and a trial follow-up phase (month 7–12). The
study was approved by the Medical Ethics Committee of Maastricht
University Medical Center, written informed consent was obtained, and
the study was registered at isrctn.com (identifier: ISRCTN 67561918). A
detailed description about the study design and main outcomes are
provided elsewhere (Lemmens et al., 2015, 2011).
2.2. Treatments and therapists
CT and IPT were carried out using the guidelines by Beck et al.
(1979) for CT, and the guidelines by Klerman et al. (1984) for IPT.
Participants received 16–20 sessions of 45min (17 sessions on average,
SD =2.9) by ten experienced licensed psychologist, psychotherapists,
and psychiatrists (9.1 years of clinical experience on average, SD =5.4,
range 4–21 years). Therapists were already trained in the treatment
modality that they delivered in the study, but received additional
training (2× 8 h) by Steven Hollon (CT) and John Markowitz (IPT)
prior to the start of the study, and delivered exclusively CT or IPT.
Sessions were scheduled weekly and allowed to be less frequent
planned towards the end of therapy. All sessions were videotaped and a
random selection of 106 tapes were examined on treatment competence
(i.e. quality of treatment) and adherence (i.e. therapy-specific behavior)
by independent raters. Treatment competence was rated good to ex-
cellent using the Cognitive Therapy Scale for CT (Dobson et al., 1985,M
=3.31, SD =0.93) and the short version of the IPT Adherence and
Quality Scale for IPT (Stuart, 2011, M =3.50, SD =0.70). The Colla-
borative Study Psychotherapy Rating Scale version 6 (Hollon et al.,
1984, 1988) indicated significant differences in therapy-specific beha-
vior between CT and IPT with higher CT-specific behavior in CT as
compared to IPT (M =80.80, SD =25.64 vs. M =52.42, SD =13.00
t=7.23, p < 0.001), and higher IPT-specific behavior in IPT as com-
pared to CT (M =85.75, SD =23.22 vs. M =44.57, SD =15.06,
t=10.79, p < 0.001) (Lemmens et al., 2015). Anxiety disorders,
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phobic anxiety symptoms and anxiety symptoms did not change quality
of treatment or therapy-specific behavior of the therapists (results not
shown, all p-values> 0.3).
2.3. Measures
2.3.1. Primary outcome
The primary outcome, depression severity was measured with the
Beck Depression Inventory, second edition (Beck et al., 1996), a 21-item
self-report instrument. The total score was obtained by summing up the
items, ranging between 0 and 63, with a higher score indicated more
severe depressive symptoms. The BDI-II has shown to be a strong
screening measure for depression with high reliability and improved
concurrent, content, and structural validity (Wang and Gorenstein,
2013). The BDI-II was repeatedly assessed across the treatment phase
(BDI-II measures at the start of each therapy session), and the sub-
sequent trial follow-up phase (BDI-II measures at 7, 8, 9, 10, 11 and 12
months).
2.3.2. Comorbid anxiety
Anxiety disorders were assessed at baseline using the results of the
SCID-I (First et al., 1995). Prior to treatment, anxiety symptoms and
phobic anxiety symptoms were measured with the Brief Symptom In-
ventory (BSI) anxiety subscale and the phobic anxiety subscale re-
presenting generalized anxiety symptoms and agoraphobic symptoms
respectively. Higher scores indicated more severe symptoms (de Beurs,
2009; Derogatis and Melisaratos, 1983). The BSI is a 53-item self-report
instrument that derived from the Symptom Checklist 90 Revised and
has demonstrated to have good psychometric properties (De Beurs and
Zitman, 2005; Derogatis and Melisaratos, 1983; Khalil et al., 2011).
Therapists and participants were blind to the results of the BSI (anxiety
symptoms), but not to the outcomes of the SCID-I assessment (anxiety
disorders).
2.4. Statistical analysis
To examine pre-treatment characteristics, cutoffs for low and high
(phobic) anxiety symptoms were used based on the Dutch outpatients
population (de Beurs, 2009). Pre-treatment characteristics and (study
and treatmentI) dropout rates of individuals with and without comorbid
anxiety disorders, with low and high anxiety symptoms, and with low
and high phobic anxiety symptoms were examined with t-tests and χ2-
tests where appropriate. To examine the differential impact of anxiety
disorders, anxiety symptoms, and phobic anxiety symptoms on study
and treatment dropout for CT and IPT, logistic regression models were
applied. To confirm that the syndromal definition of anxious depression
differs from the dimensional one, anxiety symptoms (standardized
continuous score of the BSI anxiety subscale) and phobic anxiety
symptoms (standardized continuous score of the BSI phobic anxiety
subscale) were compared between individuals with and without an
anxiety disorder (t-test with Cohen's d). In addition, subgroups of in-
dividuals who met the criteria for the syndromal and dimensional de-
finition were identified, and overlap between these groups was ex-
amined with a kappa statistics.II
To analyze the impact of anxiety disorders, anxiety symptoms
(standardized continuous score of the BSI anxiety subscale) and phobic
anxiety symptoms (standardized continuous score of the BSI phobic
anxiety subscale) on BDI-II change across treatment (measured at the
start of each therapy session) and follow-up (measured at 7, 8, 9, 10, 11
and 12 months), mixed-effects models were used (Diggle et al., 2002).
Analyses were intention-to-treat, using all available data of the 151
study participants. Since sessions were allowed to be scheduled in a
flexible manner, for some participants, there was a slight overlap be-
tween treatment and trial follow-up phase (1 or 2 sessions). Due to this
overlap, BDI-II change was modeled separately for each phase. The
following fixed effects were included in the models: standardized BDI-II
baseline scores (to adjust for different BDI-II scores prior to treatment
(Lemmens et al., 2015)), time (treatment phase model: number of ses-
sions; trial follow-up phase model: time in months), treatment (centered
at CT =−0.5 or IPT = 0.5), and a time-by-treatment interaction
(difference between CT and IPT over time). Anxiety disorder diagnosis
(centered at no diagnosis =−0.5 or one or more =0.5), anxiety
symptoms (standardized continuous score of the BSI anxiety subscale)
and phobic anxiety symptoms (standardized continuous score of the BSI
phobic anxiety subscale) were subsequently added to these models to-
gether with their interactions with treatment, time and treatment-by-
time. Since previous studies showed that anxiety could affect different
types of depression change (i.e. early rapid change instead of overall
change) (Forand and Derubeis, 2013; Forand et al., 2011), different
transformations of time (linear quadratic, loglinear) were assessed for
each model with fit indices and visual inspection. For the acute phase
model with anxiety disorder diagnosis as a predictor, a curvilinear
parametrization of time (linear and quadratic slope) was considered the
best fit. All other models had the best fit with only linear slopes. For
these linear models, the endpoint of time was coded as zero (treatment
phase model: session 20; trial follow-up phase model: month 12). To
reduce multicollinearity between the linear and quadratic slopes, time
was centered midway for the curvilinear model (treatment phase
model: session 10) (Forand et al., 2011). For all models, intercepts and
slopes were allowed to be correlated and vary randomly over in-
dividuals. An autoregressive covariance structure for the residuals was
modeled, with a correction for the irregularly spaced time lags between
the sessions (Jones, 1993). Backwards elimination was applied when
the anxiety-by-treatment-by-time-interaction was not significant
(p > 0.05).
For all models, we conducted a sensitivity analysis by subsequently
adding the following variables measured at baseline to the models:
therapist, demographics (age, gender, employment, level of education),
clinical features (first or recurrent depression) and functionality (Work
and Social Adjustment Scale (W&SAS), Mundt et al., 2002), the RAND-
36 (van der Zee and Sanderman, 1993) and the EuroQol-6D (EQ-6D,
EuroQol, 1990) for the EQ-5D).
3. Results
3.1. Descriptive statistics
Pre-treatment characteristics are shown in Table 1. As described by
Lemmens et al. (2015), the baseline EQ-5D and BDI-II were borderline
significantly higher in CT as compared to IPT (t=2.00, df =148,
p=0.05 and t=1.90, df =149, p=0.06) for the complete sample.
There were no significant differences between the two conditions in
treatment (n= 36, CT n=20, IPT n= 16) and study (n= 23, CT
n=20, IPT n=16) dropout.
3.1.1. Anxiety disorders
43 out of 151 individuals were diagnosed with one (n=35; 23.2%;
CT =19, IPT =16) or two (n=8; 5.3%; CT=5, IPT = 3) anxiety
disorders. The number of individuals with anxiety disorders did not
differ between the two conditions (CT = 24, IPT =19, χ2=0.72, df
= 1, p=0.40). The most prevalent anxiety disorder was panic disorder
(n=18), followed by social phobia (n=16), specific phobia (n=7),
I Treatment dropout was defined as discontinuation of treatment; study dropout was
defined as discontinuation of study participation.
II For the dimensional criteria (MDD plus subthreshold anxiety symptoms) the BSI
anxiety subscale was used and not the BSI phobic anxiety subscale. We choose this sub-
scale since these items overlapped most with the somatic and physic anxiety subscales of
the Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale that are often
used to assess the dimensional criteria. Since guidelines for the appropriate thresholds of
the BSI anxiety subscale for the dimensional definition were lacking, the analyses were
repeated with different cutoffs based on a Dutch outpatient population (de Beurs, 2009).
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post-traumatic stress disorder (n=6), generalized anxiety disorder
(n=2), agoraphobia without panic disorder (n=1), obsessive com-
pulsive disorder (n=1) and anxiety disorder not otherwise specified
(n=1). As shown in Table 1, individuals with a comorbid anxiety
disorder were significantly younger compared to individuals without a
comorbid anxiety disorder (t=2.62, df = 149, p=0.0098).
3.1.2. Anxiety symptoms and phobic anxiety symptoms
36 of 151 individuals scored above the ‘high anxiety symptoms
cutoff’ (de Beurs, 2009) on the BSI anxiety subscale and the number of
individuals with high anxiety symptoms did not significantly differ
between CT and IPT (CT =17, IPT =19, χ2=0.18, df = 1, p=0.67).
For the BSI phobic anxiety subscale, 26 of 151 individuals scored above
the ‘high phobic anxiety symptoms cutoff’ (de Beurs, 2009) and ap-
peared to be equally divided between CT and IPT as well (CT =13, IPT
= 13, χ2=0.0014, df = 1, p=0.970). As presented in Table 1, par-
ticipants with high anxiety symptoms and high phobic anxiety symp-
toms were significantly younger (t=2.30, df = 149, p=0.03 and
t=2.59, df = 149, p=0.01), had higher baseline depression severity
(t=−6.23, df = 149, p < 0.001 and t=−3.88, df = 149,
p=0.002), and lower quality of life measured with the EQ-5D
(t=3.17, df = 148, p=0.002 and t=2.19, df = 148, p=0.03) as
compared to individuals with low anxiety symptoms and low phobic
anxiety symptoms respectively.
3.2. Comparing the syndromal and dimensional definition of anxious
depression
Individuals with an anxiety disorder scored significantly higher on
the BSI anxiety subscale as compared to individuals without an anxiety
disorder (M =1.58, SD =0.81 vs. M =1.29, SD =0.79, t=−2.0, df
= 149, p=0.05, Cohen's d =−0.36). In addition, scores on the BSI
phobic anxiety subscale were higher for individuals with an anxiety
disorder compared to individuals without an anxiety disorder (M
=1.36, SD =0.81 vs. M =0.81, SD =0.71, t=−4.13, df = 149,
p=0.0001, Cohen's d =−0.74). However, when dividing the sample
into subgroups of syndromal and dimensional defined anxious depres-
sion and non-anxious depression, little agreement was found between
the syndromal and dimensional subgroups with kappa statistics ranging
between − 0.003 and 0.16.
3.3. The impact of anxiety disorders on BDI-II change and dropout
Table 2 provides the estimates of the mixed-effect models examining
the impact of anxiety disorders on BDI-II change for the treatment
phase (0 – 7 months) and the trial follow-up phase (7 – 12 months). For
the treatment phase model, there was a significant three way interac-
tion between anxiety disorder status, condition and the quadratic time
slope, indicating higher BDI-II scores for individuals with an anxiety
disorder receiving IPT as compared to CT. This effect is illustrated by
Fig. 1, where the raw means of the BDI-II scores are plotted and show a
curvilinear unfavorable course for IPT as compared to the CT group.
This differential effect was not found in the trial follow-up phase.
Sensitivity analyses did not change these results.
For individuals with a comorbid anxiety disorder the proportion of
treatment dropouts was significantly higher (n = 17, 39.5%) as com-
pared to individuals without a comorbid anxiety disorder (n = 19,
17.6%, χ2= 8.16, df = 1, p= 0.004), although this difference was not
found for study dropouts (χ2 = 1.51, df = 1, p = 0.219). As indicated
by the non-significant treatment by anxiety disorder interactions in the
logistic regression models, no differential effects between CT and IPT
were found for both treatment (β = 0.67, p = 0.409) and study (β = -
0.23, p = 0.807) dropout.
3.4. The impact of anxiety symptoms and phobic anxiety symptoms on BDI-
II change and dropout
Table 3 summarizes the effects of anxiety symptoms (standardized
continuous score of the BSI anxiety subscale) and phobic anxiety
symptoms (standardized continuous score of the BSI phobic anxiety
subscale) on BDI-II change as estimated with separate linear mixed-
effects models. Initially, there was no (differential) effect of anxiety
symptoms on BDI-II change in both conditions during treatment and
trial follow-up phase. However, after eliminating the anxiety symptoms
x time x condition interaction from the treatment phase model, a sig-
nificant anxiety symptoms x condition interaction appeared, indicating
overall higher BDI-II scores for IPT compared to CT. Fig. 2 illustrates
this lower order effect with mean BDI-II scores during the treatment
phase. This effect was not found in the trial follow-up phase. Phobic
anxiety did not affect BDI-II change and backwards elimination did not
alter the lower order effects significantly. Sensitivity analyses did not
Table 2
Results of mixed-effect models estimating the impact of baseline anxiety disorder(s) on repeated Beck Depression Inventory-II measurements for CT and IPT during treatment and trial
follow-up phase.
Treatment phase (BDI-II measurements at the start of each therapy
session)*
Trial follow-up phase (BDI-II measurements at 7, 8, 9, 10, 11 and 12
months)**
Fixed effect Random effect Fixed effect Random effect
β S.E. p Var. SE β S.E. p Var. SE
Intercept 19.72 0.84 < 0.001 72.00 9.56 15.02 1.21 <0.001 124.72 18.23
BDI-II baseline 7.33 0.52 < 0.001 5.27 0.94 <0.001
Condition 3.31 1.69 0.051 2.33 2.44 0.340
Time −0.83 0.08 < 0.001 0.43 0.09 −0.02 0.16 0.913 0.12 0.10
Time × condition 0.44 0.16 0.006 0.13 0.31 0.670
Time2 0.001 0.001 0.838
Time2 × condition 0.01 0.01 0.435
Anxiety Disorder (AD) −0.19 1.69 0.912 −1.18 2.45 0.629
AD × condition 3.93 3.37 0.243 1.60 4.85 0.741
AD × time −0.10 0.16 0.518 −0.07 0.31 0.831
AD × condition × time 0.51 0.32 0.113 −0.76 0.62 0.221
AD × time2 0.001 0.01 0.935
AD × condition × time2 0.09 0.03 0.001
SE, Standard Error; Var., variance, BDI-II, Beck Depression Inventory second edition; AD, Anxiety Disorder; BDI-II baseline, standardized BDI-II score at baseline; time, linear slope; time2,
quadratic slope.
* model with a linear and a quadratic slope (best fit). Time is centered midway (at session 10).
** model with only a linear slope (best fit). The endpoint of time was coded as zero (at month 12).
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change the results. Treatment dropout rates did not differ between in-
dividuals with low and high anxiety symptoms (χ2= 0.04, df = 1,
p=0.852). However, there were significantly higher study dropout
rates for individuals with high anxiety symptoms (27.8%) as compared
to low anxiety symptoms (11.3%, χ2=5.76, df = 1, p=0.02). No
differences in treatment and study dropout rates were found between
individuals with low and high phobic anxiety symptoms (χ2=2.01, df
= 1, p=0.16 and χ2= 1.50, df = 1, p=0.22). As indicated by the
non-significant treatment by anxiety symptoms interactions in the lo-
gistic regression models, no differential effects between CT and IPT
were found for both treatment (β=0.06, p=0.474) and study
(β=0.02, p=0.798) dropout. For phobic anxiety symptoms, non-
significant interactions for treatment (β=0.02, p= 0.837) and study
(β=−0.07, p= 0.549) dropout were found as well.
4. Discussion
The main goal of the current study was to determine the influence of
comorbid anxiety on the effectiveness and treatment completion of CT
and IPT for MDD. Our most important findings were that, in the
treatment phase, anxiety disorders and anxiety symptoms were asso-
ciated with better depression change in CT as compared to IPT, and that
individuals with anxiety disorders (but not anxiety symptoms) were
more likely to dropout during both treatments.
The finding that anxiety disorders and anxiety symptoms had a less
favorable impact on depression change for IPT as compared to CT in the
treatment phase, was not completely unexpected. Although no previous
head-to-head comparisons were available, comorbid anxiety have been
found to negatively impact MDD outcome for IPT (Brown et al., 1996;
Frank et al., 2011, 2000; Young et al., 2006), in contrast to the absence
Table 3
Results of mixed-effect models estimating the impact of baseline anxiety symptoms and phobic anxiety symptoms on repeated Beck Depression Inventory-II (BDI-II) measurements for CT
and IPT during treatment and trial follow-up phase.
Treatment phase (BDI-II measurements at the start of each therapy
session)
Trial follow-up phase (BDI-II measurements at 7, 8, 9, 10, 11 and 12
months)
Fixed effect Random effect Fixed effect Random effect
β S.E. p Var. SE β S.E. p Var. SE
Anxiety Symptoms (AS) 0.89 1.38 0.519 1.37 1.28 0.164
Intercept 11.54 1.30 <0.001 205.13 31.42 15.25 1.06 < 0.001 123.18 18.00
BDI-II baseline 6.45 0.65 <0.001 3.86 1.16 0.001
Time −0.81 0.07 <0.001 0.44 0.09 −0.003 0.13 0.998 0.12 0.09
Condition 5.41 2.63 0.039 2.10 2.12 0.323
Time × condition 0.34 0.14 0.013 0.36 0.27 0.179
AS × time −0.027 0.07 0.691 −0.19 0.14 0.164
AS × condition* 2.30 1.04 0.028 0.12 1.84 0.946
Phobic Anxiety Symptoms (PAS) 0.60 1.38 0.664 −0.10 1.21 0.934
Intercept 11.62 1.32 <0.001 210.19 31.96 15.21 1.06 < 0.001 124.77 18.07
BDI-II baseline 7.33 0.60 <0.001 4.45 1.07 < 0.001
Time −0.81 0.07 <0.001 0.44 0.09 −0.004 0.13 0.973 0.12 0.09
Condition 5.32 2.64 0.044 2.17 2.13 0.309
Time × condition 0.33 0.14 0.016 0.30 0.27 0.252
PAS × time 0.03 0.07 0.721 −0.37 0.14 0.007
PAS × condition −0.45 2.71 0.868 −2.23 2.17 0.303
PAS × condition × time −0.12 0.14 0.406 −0.42 0.27 0.121
SE, Standard Error; Var., variance, BDI-II, Beck Depression Inventory second edition; BDI-II baseline, standardized BDI-II score at baseline; AS, Anxiety Symptoms, standardized Anxiety
Subscale score of the Brief Symptom Inventory; PAS, Phobic Anxiety Symptoms, standardized Phobic Anxiety Subscale score of the Brief Symptom Inventory. The endpoint of time was
coded as zero (session 20 for the treatment phase model and month 12 for the trial follow-up phase model).
* Model with elimination of the anxiety-by-treatment-by-time-interaction: lower order effects appeared to be significant.
Fig. 1. Mean Beck Depression Inventory -II (BDI-II) scores for individuals with and without an anxiety disorder for Cognitive Therapy and Interpersonal Psychotherapy during the
treatment phase. Data were available for 149, 142, 124, 89 and 25 individuals at session 1, 5, 10, 15 and 20 respectively (partly due to treatment termination).
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of adverse effects of anxiety for CT (Brent et al., 1998; de Azevedo
Cardoso et al., 2014; Forand and Derubeis, 2013; Forand et al., 2011;
Fournier et al., 2009; Kashdan and Roberts, 2011; McEvoy and Nathan,
2007; Persons et al., 2006; Rohde et al., 2001; Smits et al., 2009). In
addition, there is evidence that CT outperformed IPT in the treatment of
panic disorder (Vos et al., 2012) and social anxiety disorder (Stangier
et al., 2011). A possible explanation for these differences is the focus on
exposure in CT through “in vivo” homework assignments. The moder-
ating effect of anxiety however was not found across five months
follow-up indicating no differential effects in the long term. A possible
interpretation of these follow-up findings could be that the impact of
IPT took longer to manifest as compared to CT, but is equally effective
for anxious depression at the longer term. Similar temporal patterns
and differences between CT and IPT were also found in two randomized
controlled trials on bulimia nervosa. In these trials, CT appeared to be
more effective than IPT in reducing symptoms at the end of therapy.
However, these differences were not found during follow-up (Agras
et al., 2000; Fairburn et al., 1993). Possibly, these temporal differences
could reflect specific mechanisms of change of CT and IPT. To better
understand the discrepancies between our treatment and follow-up
phase outcomes, further CT versus IPT comparisons on anxious de-
pression are needed with longer follow-up durations and the inclusion
of possible mediating variables that could explain different mechanism
of change.
The higher treatment dropout rates for individuals with comorbid
anxiety disorders have been found in some (Arnow et al., 2007; Brown
et al., 1996; Howland et al., 2009), but not all (Forand et al., 2011;
Kashdan and Roberts, 2011; Rohde et al., 2001; Schindler et al., 2013;
Smits et al., 2009) previous studies. One could explain these higher
dropout rates as a form of avoidance behavior, a key feature of anxiety
disorders (American Psychiatric Association, 2013). In contrast to our
hypothesis, no differential effects of anxiety symptoms on dropout rates
were found between CT and IPT.
In our study, we also found that the two different (syndromal and
dimensional) definitions for anxious depression define two different
groups of individuals. This is line with the results of a previous study
(van der Veen et al., 2014) and further supported by the differences we
found for pre-treatment depression severity and quality of life with a
more severe clinical picture for individuals with the dimensional defi-
nition of anxious depression. As mentioned before, a plausible ex-
planation for these differences is that the syndromal criteria identify
two distinct disorders (MDD and anxiety disorder), while the dimen-
sional criteria identify a more severe (anxious) subtype of MDD. Logi-
cally, one of the exclusion criteria for a DSM anxiety disorder is “not
better accounted for by another mental disorder”, so the anxiety cannot
be part of the depression symptomatology. With the central position of
anxiety symptoms in MDD (Ten Have et al., 2016), one could argue that
anxious depression should only be defined with dimensional criteria
(Ionescu et al., 2013; Silverstone and von Studnitz, 2003), which is also
in accordance to the newly proposed DSM-5 ‘anxious distress specifier’
for the diagnosis of MDD (American Psychiatric Association, 2013).
To our knowledge this is the first study that examined anxious de-
pression determined by both syndromal and dimensional criteria in a
head-to-head comparison of CT and IPT. Other strengths of our study
are the random allocation, the relative large sample size, and the
multiple assessments of depressive symptoms that were analyzed with
state of the art mixed models (Lemmens et al., 2015). The current study
also has some limitations. First, no inter-reliability data for the SCID-I
was collected and patients and therapist were not blind for the results of
the SCID-I. Therapists were blind for the results of the BSI anxiety
subscale and phobic anxiety subscale. Although therapists were not
instructed to adapt treatments if comorbid anxiety was present, this
knowledge could have altered treatment strategies. However, our
competence and adherence check revealed no impact of comorbid an-
xiety on quality of treatment or therapy specific behavior. Second, our
treatment and the trial follow-up phase models slightly overlap since a
few participants had one or two therapy session during the trial follow-
up phase. Third, although the overall dropout rates of the current study
were low, individuals with anxiety disorders had relatively high
dropout rates. Due to the use of mixed models, this is unlikely to affect
our findings drastically. However, we think that larger sample sizes of
individuals with comorbid anxiety disorders are warranted. In addition,
the presence of these high dropout rates is an informative and clinically
relevant finding.
The findings of this study have significant clinical implications.
Most importantly, the presence of anxiety disorders and anxiety
symptoms should be considered when selecting an effective psy-
chotherapy for a depressed individual. Based on these results, a pre-
ference to CT over IPT is justifiable. Selecting the best treatment option
for a given individual, is in line with the “personalized medicine”
movement in health care research and practice today (Simon and Perlis,
2010). If IPT is the first choice of treatment for other reasons, clinicians
could also consider to use a modified version of IPT that includes
cognitive-behavioral strategies to target symptoms of panic, anxiety
and avoidance that interfere with interpersonal problem solving
(Cyranowski et al., 2005). Another important clinical implication is that
the patient's adherence to therapy should be carefully monitored when
a comorbid anxiety disorder is diagnosed. With the assessment of other
Fig. 2. Mean Beck Depression Inventory -II (BDI-II) scores for individuals with low and high anxiety symptoms for Cognitive Therapy and Interpersonal Psychotherapy during the
treatment phase. Data were available for 149, 142, 124, 89 and 25 individuals at session 1, 5, 10, 15 and 20 respectively (partly due to treatment termination).
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predictors of treatment drop-out (e.g. ethnic minority status, younger
age, lower income, low motivation for change, poor therapeutic alli-
ance, low treatment credibility and failure to improve early in treat-
ment (Arnow et al., 2007; Cooper and Conklin, 2015; Schindler et al.,
2013; Taylor et al., 2012)), individual risks for dropout should be es-
timated, and specific interventions to prevent dropout can be con-
sidered, for example motivational interviewing techniques (Miller and
Rollnick, 2002). Another issue is that based on our finding that anxiety
symptoms are associated with more severe depressive symptomatology
and lower quality of life prior to treatment, a clinician can be con-
fronted with significant levels of distress when anxiety symptoms are
present. To deal with this more severe clinical picture, combination
therapy (psychotherapy and pharmacotherapy) can be considered,
since it has been formulated as the treatment of choice for severe de-
pression (NICE, 2009). Finally, when depression and anxiety co-occur,
transdiagnostic approaches for both CT and IPT focussing both on de-
pressive and anxiety symptoms show promising results (Newby et al.,
2015; Wright et al., 2014).
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